Joint pain reduction ‐ not reported · participants with tophi in gout
The review found no eligible studies for this question.
1 finding from 1 review
Mean sUA at end of 12 months · participants with tophi in gout
1 finding from 1 review
Proportion with complete resolution of a target tophus · participants with tophi in gout
Lesinurad 400 mg plus febuxostat CROSS showed no clear difference in proportion with complete resolution of a target tophus compared with lesinurad 200 mg plus febuxostat CROSS (low certainty).
1 finding from 1 review
Total adverse events · participants with tophi in gout
Lesinurad 400 mg plus febuxostat CROSS showed no clear difference in total adverse events compared with lesinurad 200 mg plus febuxostat CROSS (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · participants with tophi in gout
Lesinurad 400 mg plus febuxostat CROSS showed no clear difference in number of participant withdrawals due to adverse events compared with lesinurad 200 mg plus febuxostat CROSS (low certainty).
1 finding from 1 review
Mean sUA at end of 12 months · participants with tophi in gout
1 finding from 1 review
Quality of life ‐ not reported · participants with tophi in gout
The review found no eligible studies for this question.
1 finding from 1 review
Serum urate normalisation ‐ not reported · participants with tophi in gout
The review found no eligible studies for this question.
1 finding from 1 review
Function ‐ not reported · participants with tophi in gout
The review found no eligible studies for this question.
1 finding from 1 review
Withdrawals due to adverse events · participants with tophi in gout
Pegloticase every two weeks (biweekly) probably leads to higher number of participant withdrawals due to adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Total adverse events · participants with tophi in gout
Pegloticase every two weeks (biweekly) showed no clear difference in total adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Proportion with complete resolution of a target tophus · participants with tophi in gout
Monthly pegloticase showed no clear difference in proportion with complete resolution of tophi compared with placebo (moderate certainty).
1 finding from 1 review
Joint pain reduction ‐ not reported · participants with tophi in gout
The review found no eligible studies for this question.
1 finding from 1 review
Intervention not reported
Pain. WOMAC normalised to 0‐20 pain scale based on largest study reporting the 0‐20 scale (Hurley 2007). Lower score indicated less pain. Mean duration of · people with chronic hip, knee or hip and knee osteoarthritis
1 finding from 1 review
Intervention not reported
Physical function. WOMAC function scales normalised to 0‐100. Lower score indicated improved physical function. Mean duration of · people with chronic hip, knee or hip and knee osteoarthritis
1 finding from 1 review
Intervention not reported
Self‐efficacy. Self‐efficacy scores transformed to exercise beliefs score with score range from 17 to 85. Higher score indicated greater self‐efficacy. Mean duration of · people with chronic hip, knee or hip and knee osteoarthritis
1 finding from 1 review
Intervention not reported
Depression. Depression scores were transformed to the HADS depression scale with score range of 0‐21. Lower score indicated less depression. Mean duration of · people with chronic hip, knee or hip and knee osteoarthritis
1 finding from 1 review
Intervention not reported
Anxiety. HADS scale of 0‐21. Lower score indicated lower anxiety levels. Mean duration of · people with chronic hip, knee or hip and knee osteoarthritis
1 finding from 1 review
Intervention not reported
SF‐36 social function. Domain of SF‐36 considered representative of quality of life: mental health domain largely covered by depression and anxiety above: scale of 0‐100. Higher score indicated improved social function. Mean duration of · people with chronic hip, knee or hip and knee osteoarthritis
1 finding from 1 review
Intervention not reported
Adverse effects of treatment · people with chronic hip, knee or hip and knee osteoarthritis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found